Factors associated with the initiation of alpha-interferon treatment in Medicaid patients diagnosed with hepatitis C

Journal of Viral Hepatitis

Volumn 12, Issue 2, 2005, Pages 176-185

  Markowitz, Jeffrey S ^a   Gutterman, E M ^a   Hodes, D ^b   Klaskala, W ^b  

^a Health Data Analytics   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

Alpha interferon; Epidemiology; Health care claims; Hepatitis C; Medicaid; Treatment

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; NEUROLEPTIC AGENT; PEGINTERFERON ALPHA2B; PSYCHOTROPIC AGENT; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGE; AGED; ARTICLE; CASE CONTROL STUDY; CHILD; CHRONIC LIVER DISEASE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; ETHNOLOGY; FEMALE; HEALTH CARE UTILIZATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFANT; KIDNEY DISEASE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MEDICAID; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PSORIASIS; SUBSTANCE ABUSE; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ADULT; AGED; CALIFORNIA; CASE-CONTROL STUDIES; CHILD; CONFIDENCE INTERVALS; FEMALE; HEALTH CARE COSTS; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MEDICAID; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PATIENT SELECTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME;

EID: 14844301690     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2005.00607.x     Document Type: Article

References (42)

1. Everson GT, Weinberg H. Living with Hepatitis C: A Survivor's Guide, 3rd edn. New York: Hatherleigh Press, 2002.
2. National Digestive Diseases Information Clearinghouse (NIDDK). Chronic Hepatitis C: Current Disease Management. NIH Pubication No. 03-4230. February 2003. http:// www.niddk.nih.gov/health/digest/pubs/chrnhepc/chrn-hepc.htm (accessed on 5/7/2003).
3. Seeff LB, Hoofnagle JH. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis 2003; 7: 261-287.
4. Fried MW, Shiffman ML, Reddy R et al. Peginterferon alfa-2 a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
5. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-965.
6. Roche Pharmaceuticals. Product information for PEGASYS©. Roche Pharmaceuticals. December, 2002. URL: http://www.rocheusa.com/products/pegasys/ pi.pdf (accessed on 2/5/2003).
7. Bonaccorso S, Puzella A, Marino V et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res 2001; 105: 45-55.
8. Downs AM, Dunhill MG. Exacerbation of psoriasis by interferon-alpha therapy for hepatitis C. Clin Exp Dermatol 2000; 25: 351-352.
9. Georgetson MJ, Yarze JC, Lalos AT et al. Exacerbation of psoriasis due to interferon-alpha treatment of chronic active hepatitis. Am J Gastroenterol 1993; 88: 1756-1758.
10. Taylor C, Burns DA, Wiselka MJ. Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis C. Postgrad Med J 2000; 76: 365-367.
11. Unoki H, Moriyama A, Tabaru A et al. Development of Sjogren's syndrome during treatment with recombinant human interferon-alpha-2b for chronic hepatitis C. J Gastroenterol 1996; 31: 723-727.
12. Passos de Souza E, Evangelista Segundo PT, Jose FF et al. Rheumatoid arthritis induced by alpha-interferon therapy. Clin Rheumatol 2001; 20: 297-299.
13. Pittau E, Bogliolo A, Tinti A et al. Development of arthritis and hypothyroidism during alpha-interferon therapy for chronic hepatitis C. Clin Exp Rheumatol 1997; 15: 415-419.
14. Muir AJ, Provenzale D. A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol 2002; 34: 268-271.
15. Nguyen HA, Miller AI, Dieperink E et al. Spectrum of disease in US veteran patients with hepatitis C. Am J Gastroenterol 2002; 97: 1813-1820.
16. Nicklin DE, Schultz C, Brensinger CM et al. Current care of hepatitis C-positive patients by primary care physicians in an integrated delivery system. J Am Board Fam Pract 1999; 12: 427-500.
17. Rosenberg DM, Cook SF, Lanza LL. Health care, treatment patterns and cost of services for patients infected with chronic hepatitis C virus in a large insured New England population. J Viral Hepat 2000; 7: 361-367.
18. Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. Littleton. MA: PSG Publishing Company, Inc., 1985.
19. Strader DB. Understudied populations with hepatitis C. Hepatology 2002; 36(5 Suppl 1): S226-S236.
20. ICD-9-CM. Professional for Hospitals, Vol. 1, 2 and 3. In: Hart AC, Hopkins AC (eds). International Classification of Diseases, Clinical Modification, 9th revision, 6th edn. Salt Lake City, UT: Ingenix/St. Anthony Publishing/Medicode, 2002; 1: 13.
21. Kelsey JL, Whitemore AS, Evans AS et al. Methods in Observational Epidemiology, 2nd edn. New York: Oxford University Press, 1996.
22. Szklo M, Nieto FJ. Epidemiology: Beyond the Basics. Gaithersburg, MD: Aspen Publishers, Inc, 2000.
23. Kleinbaum DG, Kupper LL, Morgentern H. Epidemiologic Research: Principles and Quantitative Methods. Belmont, CA: Lifetime Learning Publications, 1982.
24. Koskinas J, Merkouraki P, Manesis E et al. Assessment of depression in patients with chronic viral hepatitis: effect of Interferon treatment. Dig Dis 2002; 20: 284-288.
25. Kraus MR, Schafer A, Faller H et al. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003; 64: 708-714.
26. Zdilar D, Franco-Bronson K, Buchler N et al. Hepatitis C, interferon alfa, and depression. Hepatology 2000; 31: 1207-1211.
27. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373-383.
28. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM Administrative databases. J Clin Epidemiolol 1992; 45: 613-619.
29. Stokes ME, Davis CS, Koch GG. Categorical Data Analysis using the SAS System. Cary, NC: SAS Institute Inc., 1995.
30. National Institute of Health Consensus Statement. Management of Hepatitis C: 2002, Vol. 19, No 1, June 10-12, 2002. http://consensus.Nih.gov/cons/116/ 116cdc_intro. htm (accessed on 5/1/2003).
31. Capuron L, Hauser P, Hinze-Selch D, Miller AH, Neveu PJ. Treatment of cytokine-induced depression. Brain Behav Immun 2002; 16: 575-580.
32. Musselman DL, Lawson DH, Gumnick JF et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344: 961-966.
33. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000; 157: 867-876.
34. Hauser P, Khosla J Aurora H et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002; 7: 942-947.
35. Harris HE, Ramsay ME, Andrews N et al. Clinical course of hepatitis C virus during the first decade of infection: cohort study. Br Med J 2002; 324: 1-6.
36. Minola E, Prati D, Suter F et al. Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood 2002; 99: 4588-4591.
37. Hamada H, Yatsuhashi H, Yano K et al. Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C. Cancer 2002; 95: 331-339.
38. Fleiss JL. Statistical Methods for Rates and Proportions, 2nd edn. New York: John Wiley & Sons, 1981.
39. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36(5 Suppl 1): S21-S29.
40. Licata A, Di Bona D, Schepis F et al. When and how to treat acute hepatitis C? J Hepatol 2003; 39: 1056-1062.
41. Kirking DM, Ammann MA, Harrington CA. Comparison of medical records and prescription claims flies in documenting prescription medication therapy. J Pharmacoepidemiol 1996; 5: 3-15.
42. West SL, Strom BL, Poole C. Validity of pharmacoepidemiology drug and diagnosis data. In: Strom BL, ed. Pharmacoepidemiology (third edition). New York: John Wiley & Sons, Ltd, 2000: 661-706.